|Day's range||15.82 - 17.23|
|52-week range||10.45 - 35.04|
|PE ratio (TTM)||19.75|
|Earnings date||23 Aug. 2017|
|Dividend & yield||0.31 (3.10%)|
|1y target est||16.64|
WOBURN, Mass.--(BUSINESSWIRE)-- Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX.AX - News), a leading manufacturer of targeted liver cancer therapies, today announced the Combined FOXFIRE Analysis that evaluated SIR-Spheres Y-90 resin microspheres in combination with chemotherapy in patients with mCRC did not improve overall survival compared to chemotherapy alone. The Combined FOXFIRE Analysis is comprised of data from the SIRFLOX study first presented in 2015 and data from two new studies – FOXFIRE and FOXFIRE-Global.
Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases WOBURN, Mass.--Sirtex Medical Limited (ASX: SRX) today announced ...
Results will provide doctors and cancer researchers with insights to improve liver cancer treatment now, and in the future ELPA has recently joined a special partnership with similar organisations across ...